These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35128632)

  • 1. Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib.
    Zhou A; Kong T; Fowles JS; Jung CL; Allen MJ; Fisher DAC; Fulbright M; Nemeth E; Ganz T; Oh ST
    Br J Haematol; 2022 May; 197(4):e49-e52. PubMed ID: 35128632
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib: the first agent approved for myelofibrosis.
    Verstovsek S
    Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
    [No Abstract]   [Full Text] [Related]  

  • 3. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
    Martí-Carvajal AJ; Anand V; Solà I
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010298. PubMed ID: 25860512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
    Ikeda Y; Yamanouchi J; Takenaka K
    Ann Hematol; 2021 Oct; 100(10):2639-2641. PubMed ID: 32676732
    [No Abstract]   [Full Text] [Related]  

  • 6. A neutrophilic dermatosis following treatment of myelofibrosis with ruxolitinib: An emerging phenomenon?
    Jiang M; Tran AK; Marshman G
    Australas J Dermatol; 2021 Nov; 62(4):e607-e609. PubMed ID: 34529266
    [No Abstract]   [Full Text] [Related]  

  • 7. Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience.
    Gangat N; McCullough K; Al-Kali A; Begna KH; Patnaik MM; Litzow MR; Hogan W; Shah M; Alkhateeb H; Mangaonkar A; Foran JM; Palmer JM; Pardanani A; Tefferi A
    Br J Haematol; 2022 Aug; 198(4):e54-e58. PubMed ID: 35614565
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.
    Guglielmelli P; Ghirardi A; Carobbio A; Masciulli A; Maccari C; Mora B; Rumi E; Triguero A; Finazzi MC; Pettersson H; Paoli C; Mannelli F; Vanni D; Rambaldi A; Passamonti F; Alvarez-Larràn A; Andreasson B; Vannucchi AM; Barbui T
    Blood Adv; 2022 Jan; 6(2):373-375. PubMed ID: 34753179
    [No Abstract]   [Full Text] [Related]  

  • 9. Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story.
    Barosi G; Gale RP
    Blood Adv; 2022 Apr; 6(7):2331-2333. PubMed ID: 35240682
    [No Abstract]   [Full Text] [Related]  

  • 10. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
    Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
    Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort.
    Scalzulli E; Ielo C; Luise C; Musiu P; Bisegna ML; Carmosino I; Assanto GM; Martelli M; Breccia M
    Blood Adv; 2022 Aug; 6(15):4424-4426. PubMed ID: 35737865
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.
    Passamonti F; Heidel FH; Parikh RC; Ajmera M; Tang D; Nadal JA; Davis KL; Abraham P
    Future Oncol; 2022 Jun; 18(18):2217-2231. PubMed ID: 35388710
    [No Abstract]   [Full Text] [Related]  

  • 13. Ruxolitinib for the treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Drugs Today (Barc); 2011 Nov; 47(11):817-27. PubMed ID: 22146225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib with Navitoclax Is Efficacious and Safe in Myelofibrosis.
    Cancer Discov; 2022 May; 12(5):OF4. PubMed ID: 35491635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
    N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case-report, literature review, and French pharmacovigilance data.
    Moutel M; Noel V; Jary A; Le QH; Lier C; Viguier M; Lebbe C; Azzouz B; Bani-Sadr F
    Am J Hematol; 2022 Jan; 97(1):E31-E34. PubMed ID: 34724250
    [No Abstract]   [Full Text] [Related]  

  • 18. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
    Yacoub A; Odenike O; Verstovsek S
    Curr Hematol Malig Rep; 2014 Dec; 9(4):350-9. PubMed ID: 25145552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.
    Soyer N; Ali R; Turgut M; Haznedaroğlu İC; Yılmaz F; Aydoğdu İ; Pir A; Karakuş V; Özgür G; Kiş C; Ceran F; İlhan G; Özkan M; Aslaner M; İnce İ; Yavaşoğlu İ; Gediz F; Sönmez M; Güvenç B; Özet G; Kaya E; Vural F; Şahin F; Töbü M; Durusoy R; Saydam G
    Turk J Med Sci; 2021 Jun; 51(3):1033-1042. PubMed ID: 33315343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.
    Di Prima A; Botticelli A; Scalzulli E; Colafigli G; Pepe S; Lisi C; Marchetti P; Martelli M; Foà R; Breccia M
    Ann Hematol; 2021 Aug; 100(8):2117-2119. PubMed ID: 32856142
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.